Sublingual versus vaginal misoprostol in the management of missed miscarriage.

OBJECTIVE To compare the efficacy of sublingual and vaginal misoprostol in the medical management of missed miscarriage. METHODS Fifty women diagnosed as having missed miscarriage of gestational age less than 20 weeks were assigned randomly to receive 400 microg of either sublingual or vaginal misoprostol every three hours, up to a maximum of five doses. The primary outcome measures were, complete evacuation of products of conception, mean induction to delivery time and the occurrence of side effects. RESULTS There was no significant difference in complete evacuation rates between the sublingual misoprostol and the vaginal misoprostol groups (52% vs. 48%, p = 0.571) mainly within the first 24 hours. Mean induction to delivery time was also similar for both groups (13.07 +/- 6.95 hours for sublingual versus 13.29 +/- 5.63 hours for vaginal group) as was the total number of doses required (4.44 +/- 1.04 for sublingual versus 4.52 +/- 0.96 for vaginal misoprostol). Side effects were seen in 18 women (72%) in the sublingual group compared to 5 women (20%) in the vaginal group (p < 0.001). The incidence of unpleasant taste was significantly higher in the sublingual group than in the vaginal group (60% versus 4%, p = < 0.001). CONCLUSION Sublingual misoprostol is as effective as vaginal misoprostol for medical management of missed miscarriage but is associated with an increased risk of side effects especially an unpleasant taste.

[1]  I. Milsom,et al.  A prospective longitudinal population‐based study of clinical miscarriage in an urban Swedish population , 2007, BJOG : an international journal of obstetrics and gynaecology.

[2]  S. Singhal,et al.  Sublingual misoprostol in management of missed abortion in India , 2007, Tropical doctor.

[3]  F. Khan,et al.  Medical Termination of First Trimester Miscarriages , 2007 .

[4]  Lucy K Smith,et al.  Economic evaluation of alternative management methods of first-trimester miscarriage based on results from the MIST trial , 2006 .

[5]  K. Barnhart,et al.  Factors Related to Successful Misoprostol Treatment for Early Pregnancy Failure* , 2006, Obstetrics and gynecology.

[6]  J. Neilson,et al.  Medical treatment for early fetal death (less than 24 weeks). , 2006, The Cochrane database of systematic reviews.

[7]  A. Templeton,et al.  A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation. , 2005, Human reproduction.

[8]  A. Templeton,et al.  A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation , 2005, BJOG : an international journal of obstetrics and gynaecology.

[9]  B. Mol,et al.  Economic evaluation of misoprostol in the treatment of early pregnancy failure compared to curettage after an expectant management. , 2005, Human reproduction.

[10]  P. Ho,et al.  A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy , 2004, BJOG : an international journal of obstetrics and gynaecology.

[11]  J. Moodley,et al.  A randomized controlled trial comparing medical and expectant management of first trimester miscarriage. , 2004, Human reproduction.

[12]  A. Templeton,et al.  A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation. , 2003, Contraception.

[13]  P. Ho,et al.  A prospective randomized study to compare the use of repeated doses of vaginal with sublingual misoprostol in the management of first trimester silent miscarriages. , 2003, Human reproduction.

[14]  P. Brain,et al.  Medical Management of Missed Abortion: A Randomized Clinical Trial , 2002, Obstetrics and gynecology.

[15]  P. Ho,et al.  Pharmacokinetics of different routes of administration of misoprostol. , 2002, Human reproduction.

[16]  K. Chia,et al.  Medical termination of missed abortion , 2002, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[17]  M. Creinin,et al.  Medical management of missed abortion: a randomized clinical trial. , 2002, Obstetrics and gynecology.

[18]  P. Ho,et al.  Vaginal misoprostol as medical treatment for first trimester spontaneous miscarriage. , 2001, Human reproduction.

[19]  P. Ho,et al.  Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: efficacy and acceptability. , 2000, Human reproduction.

[20]  R. Prasad,et al.  Does an acidic medium enhance the efficacy of vaginal misoprostol for pre-abortion cervical priming? , 1999, Human reproduction.

[21]  P. Ho,et al.  Vaginal Misoprostol Compared With Oral Misoprostol in Termination of Second‐Trimester Pregnancy , 1997, Obstetrics and gynecology.

[22]  N. Benowitz,et al.  Absorption Kinetics of Misoprostol With Oral or Vaginal Administration , 1997, Obstetrics and gynecology.

[23]  P. Ho,et al.  Vaginal administration of misoprostol is more effective than oral administration in termination of second trimester pregnancy , 1997 .